Squarepoint Ops LLC Buys Shares of 29,249 MeiraGTx Holdings plc (NASDAQ:MGTX)

Squarepoint Ops LLC bought a new stake in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 29,249 shares of the company’s stock, valued at approximately $123,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Hsbc Holdings PLC increased its position in MeiraGTx by 100.9% during the 2nd quarter. Hsbc Holdings PLC now owns 23,954 shares of the company’s stock valued at $102,000 after purchasing an additional 12,029 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of MeiraGTx by 14.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 462,950 shares of the company’s stock valued at $1,949,000 after acquiring an additional 58,854 shares in the last quarter. American Century Companies Inc. increased its stake in shares of MeiraGTx by 42.4% in the 2nd quarter. American Century Companies Inc. now owns 40,008 shares of the company’s stock valued at $168,000 after acquiring an additional 11,907 shares in the last quarter. Letko Brosseau & Associates Inc. increased its stake in shares of MeiraGTx by 38.5% in the 2nd quarter. Letko Brosseau & Associates Inc. now owns 45,300 shares of the company’s stock valued at $191,000 after acquiring an additional 12,600 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of MeiraGTx by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 52,996 shares of the company’s stock valued at $223,000 after acquiring an additional 5,178 shares in the last quarter. Institutional investors and hedge funds own 67.48% of the company’s stock.

MeiraGTx Stock Performance

NASDAQ MGTX opened at $4.25 on Monday. The company has a fifty day simple moving average of $4.16 and a 200 day simple moving average of $4.66. MeiraGTx Holdings plc has a 12-month low of $3.49 and a 12-month high of $7.60. The company has a current ratio of 2.36, a quick ratio of 2.36 and a debt-to-equity ratio of 1.04. The company has a market cap of $273.30 million, a P/E ratio of -3.63 and a beta of 1.29.

MeiraGTx (NASDAQ:MGTX) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.45). MeiraGTx had a negative net margin of 1,146.81% and a negative return on equity of 152.82%. The business had revenue of $0.28 million during the quarter, compared to analyst estimates of $16.38 million. Sell-side analysts predict that MeiraGTx Holdings plc will post -1.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on MGTX shares. Royal Bank of Canada lowered their price objective on shares of MeiraGTx from $11.00 to $9.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Chardan Capital reiterated a “buy” rating and issued a $36.00 price objective on shares of MeiraGTx in a research note on Wednesday, July 31st.

Insider Activity at MeiraGTx

In other news, Director Perceptive Advisors Llc acquired 1,250,000 shares of the business’s stock in a transaction on Monday, August 12th. The shares were purchased at an average cost of $4.00 per share, with a total value of $5,000,000.00. Following the acquisition, the director now directly owns 12,531,103 shares of the company’s stock, valued at $50,124,412. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.40% of the stock is currently owned by insiders.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.